Climb Bio Inc.’s stock-tickling event May 5 highlighting Fc-enhanced monoclonal antibody (mAb) budoprutug, followed two days later by a financial update, has kept Wall Street buzzing. Mizuho analyst ...
Scarlet Therapeutics Ltd. has demonstrated its manufactured red blood cells (RBCs) act in the same way as their natural counterparts in vivo, opening the way for the cells to be used as drug delivery ...
Climb Bio Inc. outlined May 5 an enticing data spill ahead this year with Fc-enhanced monoclonal antibody budoprutug (budo) ...
Harbour Biomed has gained IND clearance from the FDA for HBM-7004, enabling the initiation of a first-in-human phase I trial in subjects with advanced solid tumors.
Biolojic Design Ltd. has reported preclinical data for its antibody-drug conjugate (ADC) BD-200, developed using an AI-guided antibody engineering platform named Multibody.
Treeline Biosciences Inc. has disclosed macrocyclic compounds acting as RAS inhibitors that are potentially useful for the treatment of pancreatic cancer (ductal adenocarcinoma) and melanoma.
A designed chimeric virus induced broadly neutralizing antibodies (bNAbs) against the macaque equivalent of HIV. The strategy ...
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash deal worth $4.1 billion. The acquisition ...
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the ...
In its first substantial M&A transaction since 2021, Bayer AG is buying Perfuse Therapeutics Inc., a firm that has operated quietly, though it reported positive midstage data last year for PER-001, an ...
Clinical updates for biopharma and med tech, including data readouts and publications: Aptevo, Atossa, Avalo, Bioxodes, Braintree, Cairn Surgical, Eupraxia, Helio ...
It’s a sure bet when the U.S. Trade Representative releases its annual Special 301 Report that Chile, China, India, Indonesia, Russia and Venezuela will be on the Priority Watch List. The 2026 report ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results